NLRP3 and acute respiratory distress syndrome: Together, our study demonstrates that the new lipid nanomedicine (Son-lipo) alleviates ARDS through repairing the endothelial barrier and inactivating NLRP3 inflammasome, hence providing a candidate strategy for the clinical treatment of ARDS.